Development
Ekso Bionics Holdings, Inc.
EKSO
$3.14
-$0.11-3.39%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -0.78% | -2.69% | -29.65% | -38.59% | -54.44% |
| Total Depreciation and Amortization | 91.43% | 47.24% | 12.51% | -5.14% | -13.29% |
| Total Amortization of Deferred Charges | -- | 7,900.00% | 7,850.00% | -- | -- |
| Total Other Non-Cash Items | -2.69% | -18.89% | 380.46% | 199.73% | 240.40% |
| Change in Net Operating Assets | 77.40% | 3.93% | 93.59% | -6.75% | -177.42% |
| Cash from Operations | 17.93% | 0.04% | 4.66% | -9.98% | -31.66% |
| Capital Expenditure | 19.07% | -19.29% | -393.22% | -300.00% | -228.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.97% | -3,577.14% | -8,835.59% | -8,742.37% | -8,671.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -33.33% | -- | -51.35% | -75.86% | -138.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 40.21% | -34.95% | -32.65% | -48.91% | -172.18% |